Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Miglustat - Actelion Pharmaceuticals

Drug Profile

Miglustat - Actelion Pharmaceuticals

Alternative Names: AT2221; Brazaves; NB-DNJ; OGT 918; OXAIDS; SC 48334; Zavesca

Latest Information Update: 03 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oxford Glycobiology Institute
  • Developer Actelion Pharmaceuticals; National Taiwan University; Teva Pharmaceutical Industries; United Therapeutics Corporation
  • Class Alkaloids; Imino pyranoses; Small molecules
  • Mechanism of Action Alpha-glucosidase inhibitors; Glucosylceramide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gaucher's disease type I; Niemann-Pick diseases
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gaucher's disease type I; Niemann-Pick disease type C
  • Phase II Cystic fibrosis; Gaucher's disease type III
  • No development reported Hepatitis C
  • Discontinued HIV infections; Tay-Sachs disease

Most Recent Events

  • 10 Apr 2019 Actelion Pharmaceuticals plans a phase IV trial for Niemann-Pick diseases (In children, In adolescents, In adults, In the elderly) in China (PO, Capsule) in July 2019 (NCT03910621)
  • 24 Jun 2018 Biomarkers information updated
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-C in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top